drugset / Trial / NCT05312372
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determinate the safety profile, tolerability, pharmacokinetics, and preliminary antineoplastic activity of S095033 in combination with paclitaxel in participants with advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Timeline
- Start
- 2025-05
- Primary completion
- 2026-06
- Completion
- 2026-06
Outcome
Outcome not reported
Stopped (Business): “Strategic development reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S095033 | Unknown | 100 mg | — |
| Subject | S095033 | Unknown | 150 mg | — |
| Subject | S095033 | Unknown | 200 mg | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |